FIELD: medicine; hematology.
SUBSTANCE: invention can be used for acquired thrombotic thrombocytopenic purpura. Treatment is based on plasma exchange (TPE) procedures, application of glucocorticosteroids, rituximab and caplacizumab. Rituximab therapy is started after an increase in the blood platelet count of ≥ 150×109/l and termination of plasma exchange procedures. Duration of caplacizumab therapy is determined by achieving ADAMTS13 activity in blood plasma of ≥ 20 %.
EFFECT: method enables reducing the risk of disease recurrences by eliminating the possibility of rituximab elimination during TPE, as well as reducing the duration of the therapy by measuring ADAMTS13 activity in blood plasma.
7 cl, 5 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND USES THEREOF | 2015 |
|
RU2704444C2 |
| METHODS OF TREATING TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND THEIR USE | 2015 |
|
RU2807602C2 |
| METHODS FOR TREATMENT OF INITIAL EPISODE OF TTP USING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2019 |
|
RU2794143C2 |
| METHOD FOR LABORATORY DIAGNOSIS OF COVID-19 SEVERITY BY DETERMINING THE RATIO OF VON WILLEBRAND FACTOR AND ADAMTS-13 ACTIVITY | 2022 |
|
RU2774143C1 |
| METHOD OF TREATING IMMUNE THROMBOCYTOPENIA | 2018 |
|
RU2703458C1 |
| METHOD OF TREATING HUMAN SYSTEMIC LUPUS ERYTHEMATOSUS | 2024 |
|
RU2829414C1 |
| METHOD FOR PREVENTING DEVELOPING THROMBOCYTOPENIA IN PATIENTS SUFFERING CHRONIC HEPATITIS C COMBINED WITH Helicobacter pylori INFECTION AND RECEIVING COMBINED ANTIVIRAL THERAPY | 2013 |
|
RU2536285C1 |
| METHOD FOR PREDICTING THE COURSE OF PRIMARY MEDIASTINAL B-LARGE CELL LYMPHOMA | 2021 |
|
RU2772187C1 |
| METHOD FOR THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY WITH NEPHROTIC SYNDROME AND AN INCREASED LEVEL OF ANTI-PLAR2 | 2020 |
|
RU2754509C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF POST-SPLENECTOMY IMMUNE THROMBOCYTOPENIA BY SPLENIC CD8+T-LYMPHOCYTE WEIGHT | 2014 |
|
RU2563284C1 |
